Latest Period
Q2 2026
Security Snapshot
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) Institutional Ownership
CUSIP: 48301N104
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
14
Shares (Excl. Options)
967,960
Price
$0.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- KAPA on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 967,960
- Total 13F value
- $371,096
- Portfolio coverage rank
- 0%
- Share change
- +366,899
- Value change
- +$126,777
- Number of holders
- 14
- Shares outstanding
- 17,734,228
- SEC-reported price per share
- $0.30
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share is tracked under CUSIP 48301N104.
- 14 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 11 to 14 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $341,508 to $371,096.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 14 institutions filings for Q2 2026.
Security key
48301N104
Latest holder period
Q2 2026
13F holders
14
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
KAPA full holder history
Kairos Pharma, LTD. SEC filings
Kairos Pharma, LTD. company facts
Kairos Pharma, LTD. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 48301N104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
KAPA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | -50% | $628,306 | -$576,510 | 884,938 | -48% | Armistice Capital, LLC | 30 Jun 2025 |
As of 30 Jun 2026, 14 institutional investors reported holding 967,960 shares of Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA). This represents 5.5% of the company’s total 17,734,228 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 967,960 | $371,096 | +$126,777 | $0.38 | 14 |
| 2026 Q1 | 601,061 | $341,508 | -$296,840 | $0.56 | 11 |
| 2025 Q4 | 855,718 | $607,468 | +$259,407 | $0.71 | 14 |
| 2025 Q3 | 445,019 | $505,843 | +$273,129 | $1.17 | 14 |
| 2025 Q2 | 174,435 | $123,288 | -$1,296,527 | $0.71 | 9 |
| 2025 Q1 | 1,577,246 | $1,463,500 | +$857,974 | $0.94 | 8 |
| 2024 Q4 | 406,598 | $618,272 | +$548,969 | $1.52 | 5 |
| 2024 Q3 | 45,320 | $70,000 | +$70,000 | $1.53 | 2 |